Efficacy and safety profile of selumetinib in symptomatic inoperable plexiform neurofibromas
Author:
Publisher
Edizioni Minerva Medica
Subject
Neurology (clinical),Surgery
Link
https://www.minervamedica.it/pdf.php?cod=R38Y2022N06A0501
Reference23 articles.
1. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
2. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas;Jakacki RI;Neuro-oncol,2017
3. Interferon-α for Unresectable Progressive and Symptomatic Plexiform Neurofibromas
4. Trametinib therapy for children with neurofibromatosis type 1 and life‐threatening plexiform neurofibroma or treatment‐refractory low‐grade glioma
5. Nilotinib Is More Potent than Imatinib for Treating Plexiform Neurofibroma In Vitro and In Vivo
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Histopathologic features of selumetinib‐induced paronychia in a child with neurofibromatosis type 1;JEADV Clinical Practice;2023-12-21
2. Plexiform neurofibromatosis of face – Recent advances in the management;IP Indian Journal of Anatomy and Surgery of Head, Neck and Brain;2023-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3